Antirestenosis protein
AssigneeResearch Corporation Technologies, Inc.
InventorsD. Grant McFadden, Alexandra Lucas
Life of this patent
Estimating the term…
Abstract
A method of treating primary and recurrent atheromatous plaque development is provided. The method involves administering a therapeutically effective amount of SERP-1, admixed in a pharmaceutically acceptable carrier to the intimal or lumenal layer of arterial walls. Biologically active SERP-1 analogs are also provided.
Claims24
A method of treating primary or recurrent plaque development in an artery which comprises administering a therapeutically effective amount of SERP-1 directly onto an atheromatous site.
A method of treating primary plaque development in an artery which comprises delivering a therapeutically effective amount of SERP-1 the arterial endothelium.
A method of treating restenosis resulting after an arterial recanalization intervention procedure which comprises administering a therapeutically effective amount of SERP-1 at the site of recanalization.
A method of treating urethral or uretal stricture which comprises administering a therapeutically effective amount of SERP-1 to the lumenal layers of the urethra and/or uterers.
A pharmaceutical composition comprising SERP-1 admixed with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising SERP-1 having an amino acid other than asparagine at position 320.
A pharmaceutical composition comprising SERP-1 having an amino acid other than arginine at position 319 and asparagine at position 320.
A method of treating inflammation following arterial intimal injury which comprises blocking the action of SERP-1 cognate serine proteases by administering a therapeutically effective amount of SERP-1.
A method of treating inflammation following arterial intimal injury comprising administering a therapeutically effective amount of SERP-1.
Dependencies are inferred from the claim text.